Akero Therapeutics, Inc clinical trials

Acquired by Novo Nordisk A/S, Dec 9, 2025 · source ↗

The registry lists 6 studies whose lead sponsor is Akero Therapeutics, Inc. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Before and after it joined Novo Nordisk A/S

First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S: 6
First submitted after Akero Therapeutics, Inc became part of Novo Nordisk A/S: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 3
Recruiting: 2
Active, not recruiting: 1

Phase

Phase 2: 3
Phase 3: 3

Where

Puerto Rico: 6
United States: 6
Mexico: 4
Turkey: 3
Korea, Republic of: 3
Canada: 3

Registry sponsor names on this page

Akero Therapeutics, Inc6 studies

Something wrong with this grouping? Tell us on the Novo Nordisk A/S page.

Studies

Recruiting first, then most recently updated. Showing 6 of 6. All Novo Nordisk A/S studies →

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisRecruitingNCT06215716Phase 3
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHRecruitingNCT06528314Phase 3
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)CompletedNCT05039450Phase 2
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Active, not recruitingNCT06161571Phase 3
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04767529Phase 2
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT03976401Phase 2
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S